Saturday 17 October 2026
Export FEMY’s income statement to Excel — free account
Femasys Inc.
FEMY Healthcare Medical Instruments & Supplies
Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024. In the quarter to June 2026, revenue fell 18.9%, EPS grew 58.4%, free cash flow grew 11.3% and total debt rose 3,369.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.65
0.09
−5.17%
Follow FEMY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.00 | 9.93 | 11.78 | 6.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.68) | (5.44) | (6.76) | (3.57) | |
P/B ratio |
3.17 | 3.88 | 3.84 | 3.48 | |
Price to Tangible BV |
3.26 | 3.97 | 3.91 | 3.58 | |
EV/Sales |
4.84 | 8.20 | 11.16 | 7.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.51) | (1.01) | (1.47) | (0.92) | |
EV/FCF |
(0.50) | (0.98) | (1.43) | (0.90) | |
Quick Ratio |
0.49 | 2.72 | 1.76 | 0.41 | |
Current Ratio |
1.16 | 4.53 | 3.91 | 2.14 | |
Net Debt/EBITDA |
1.03 | 0.87 | 0.37 | (0.45) | |
Debt/Assets |
0.64% | 25.56% | 23.83% | 29.44% | |
Debt/Equity |
0.02 | 0.90 | 0.54 | 0.90 | |
Asset Turnover |
0.13 | 0.14 | 0.16 | 0.18 | |
Operating CF/Net income |
1.28 | 1.06 | (12.61) | 0.88 | |
Capex/Depreciation |
0.29 | (1.64) | (0.31) | (0.03) | |
Interest Coverage |
(6.87) | (11.33) | (23.92) | (27.22) | |
Research and Development Expense of Revenue |
189.47% | 222.87% | 308.17% | 586.77% | |
Selling, General and Administrative Expense of Revenue |
359.42% | 397.71% | 729.14% | 972.15% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
23.92% | 8.16% | 35.68% | 63.53% | |
Graham Net Nets |
0.04 | 0.07 | 0.11 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(204.55%) | (86.81%) | (64.29%) | (84.45%) | |
Free Cash Flow Yield |
(139.02%) | (84.35%) | (66.36%) | (128.81%) | |
Revenue per Share |
0.36 | 0.41 | 0.13 | 0.10 | |
Operating CF per Share |
(2.63) | (2.12) | (1.24) | (1.17) | |
Capex per Share |
(0.09) | (0.07) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(2.72) | (2.19) | (1.27) | (1.18) | |
Cash per Share |
2.23 | 4.69 | 1.62 | 0.43 | |
Shareholders Equity per Share |
2.22 | 2.97 | 2.19 | 1.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.22 | 2.97 | 2.19 | 1.20 | |
Free Cash Flow |
(5.58) | (4.33) | (4.22) | (3.95) | |
Working Capital |
1.71 | 12.82 | 9.19 | 4.45 | |
Capital Expenditures |
(0.19) | (0.14) | (0.08) | (0.01) | |
Net Current Asset Value |
0.51 | 1.60 | 3.14 | 0.07 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.27 | 0.17 | 0.19 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.48 | 0.55 | 0.20 | 0.20 | |
Average Payables |
1.65 | 1.62 | 1.96 | 2.80 | |
Average Inventory |
3.86 | 4.39 | 4.98 | 5.71 | |
Average Assets |
15.94 | 16.58 | 14.89 | 13.04 | |
Average Common Equity |
5.26 | 4.09 | 4.64 | 2.77 |
Columns are period end dates